Sun Pharma Advanced Research Company Limited (SPARC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sun Pharma Advanced Research Company Limited (SPARC) has a cash flow conversion efficiency ratio of 0.336x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs-1.16 Billion ≈ $-12.53 Million USD) by net assets (Rs-3.45 Billion ≈ $-37.27 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Sun Pharma Advanced Research Company Lim (SPARC) liquidity interval to measure how many days the company can operate on defensive assets alone.
Sun Pharma Advanced Research Company Limited - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Sun Pharma Advanced Research Company Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Sun Pharma Advanced Research Company Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sun Pharma Advanced Research Company Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Artis Real Estate Investment Trust
TO:AX-UN
|
0.040x |
|
Summit
TA:SMT
|
0.016x |
|
Yueyang Forest & Paper Co Ltd
SHG:600963
|
-0.032x |
|
Warom Technology Inc Co
SHG:603855
|
-0.016x |
|
Treasure ASA
OL:TRE
|
0.012x |
|
Nesco Limited
NSE:NESCO
|
0.077x |
|
Guangdong Guanhao High-Tech Co Ltd
SHG:600433
|
-0.001x |
|
Coronation Fund Managers Ltd
JSE:CML
|
0.492x |
Annual Cash Flow Conversion Efficiency for Sun Pharma Advanced Research Company Limited (2007–2025)
The table below shows the annual cash flow conversion efficiency of Sun Pharma Advanced Research Company Limited from 2007 to 2025. For the full company profile with market capitalisation and key ratios, see Sun Pharma Advanced Research Company Lim market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | Rs-2.17 Billion ≈ $-23.46 Million |
Rs-3.60 Billion ≈ $-38.96 Million |
1.661x | +148.66% |
| 2024-03-31 | Rs1.26 Billion ≈ $13.60 Million |
Rs-4.29 Billion ≈ $-46.42 Million |
-3.413x | -2431.86% |
| 2023-03-31 | Rs5.13 Billion ≈ $55.45 Million |
Rs-691.20 Million ≈ $-7.48 Million |
-0.135x | +97.98% |
| 2022-03-31 | Rs312.26 Million ≈ $3.38 Million |
Rs-2.08 Billion ≈ $-22.52 Million |
-6.669x | -838.67% |
| 2021-03-31 | Rs-1.68 Billion ≈ $-18.20 Million |
Rs-1.52 Billion ≈ $-16.43 Million |
0.903x | -92.02% |
| 2020-03-31 | Rs-186.38 Million ≈ $-2.02 Million |
Rs-2.11 Billion ≈ $-22.80 Million |
11.310x | +2048.94% |
| 2019-03-31 | Rs2.96 Billion ≈ $32.04 Million |
Rs-1.72 Billion ≈ $-18.59 Million |
-0.580x | +41.35% |
| 2018-03-31 | Rs1.85 Billion ≈ $19.98 Million |
Rs-1.83 Billion ≈ $-19.77 Million |
-0.989x | -23.37% |
| 2017-03-31 | Rs1.60 Billion ≈ $17.27 Million |
Rs-1.28 Billion ≈ $-13.85 Million |
-0.802x | +45.76% |
| 2016-03-31 | Rs299.03 Million ≈ $3.23 Million |
Rs-442.12 Million ≈ $-4.78 Million |
-1.479x | -272.84% |
| 2015-03-31 | Rs997.99 Million ≈ $10.79 Million |
Rs-395.76 Million ≈ $-4.28 Million |
-0.397x | -249.72% |
| 2014-03-31 | Rs1.39 Billion ≈ $15.06 Million |
Rs368.95 Million ≈ $3.99 Million |
0.265x | +130.12% |
| 2013-03-31 | Rs1.08 Billion ≈ $11.73 Million |
Rs-953.44 Million ≈ $-10.31 Million |
-0.879x | -184.34% |
| 2012-03-31 | Rs-666.09 Million ≈ $-7.20 Million |
Rs-694.49 Million ≈ $-7.51 Million |
1.043x | +134.07% |
| 2011-03-31 | Rs56.23 Million ≈ $608.16K |
Rs25.05 Million ≈ $270.90K |
0.445x | -50.20% |
| 2010-03-31 | Rs141.24 Million ≈ $1.53 Million |
Rs126.34 Million ≈ $1.37 Million |
0.895x | +25.38% |
| 2009-03-31 | Rs356.78 Million ≈ $3.86 Million |
Rs254.54 Million ≈ $2.75 Million |
0.713x | +256.80% |
| 2008-03-31 | Rs448.18 Million ≈ $4.85 Million |
Rs-203.92 Million ≈ $-2.21 Million |
-0.455x | -54787.50% |
| 2007-03-31 | Rs497.01 Million ≈ $5.37 Million |
Rs-412.00K ≈ $-4.46K |
-0.001x | -- |
About Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology and immunology. The company is also developing Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia th… Read more